REG - Novacyt S.A. - Appointment of CFO

Novacyt SAAnnouncement

02/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240102:nRSB2193Ya&default-theme=true

RNS Number : 2193Y  Novacyt S.A.  02 January 2024

 

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Appointment of CFO

 

Paris, France, and Eastleigh and Manchester, UK - 2 January - Novacyt S.A.
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics
company with a broad portfolio of integrated technologies and services,
announces the appointment of Steve Gibson as Chief Financial Officer with
immediate effect. Mr Gibson will become a Board Director of the Company,
subject to shareholder approval, at the Company's Annual General Meeting.

 

Steve joined Novacyt in 2017 and has served as Group Finance Director since
2020. Prior to joining Novacyt, Steve spent over 10 years in various finance
departments at Hewlett-Packard and then Hewlett Packard Enterprise in
positions of increasing seniority. Steve is a Chartered Management Accountant
(CIMA) and has more than 18 years of international commercial experience.

 

Commenting, James Wakefield, Non-Executive Chairman, said: "We are delighted
to welcome Steve as our CFO. He has impressed us with his financial and
operational expertise and was instrumental in the acquisition of Yourgene
Health plc as well as delivering the strategic changes to the Company over the
last two years. The Board looks forward to working with him as we continue to
execute our growth strategy."

 

Additional Disclosures Required under the AIM Rules for Companies

Steven Michael Gibson (aged 41) has held the following directorship or
partnerships in the past five years:

 

 Current directorships/partnerships   Previous directorships/partnerships (last five years)
 Lab21 Healthcare Limited

 Biotec Laboratories Limited

 Primer Design Limited

 Microgen Bioproducts Limited

 Novacyt UK Holdings Limited

 IT-IS International Limited

 Delta Diagnostics (UK) Limited

 Yourgene Health Limited

 Yourgene Health UK Limited

 Yourgene Genomic Services Limited

 Elucigene Limited

 Yourgene Health Canada Investments

 Yourgene Health Canada Holdings

 Yourgene Health Inc

 

 

Mr Gibson and persons closely associated (as defined under MAR) with Mr Gibson
currently hold 9,116 ordinary shares of €1/15 each in the Company.

 

Save as disclosed above, there is no further information to be disclosed in
respect of the above appointment pursuant to Rule 17 and Schedule 2 paragraph
(g) of the AIM Rules for Companies.

 

 

 

 

Contacts

 

 Novacyt SA                                                              https://novacyt.com/investors (https://novacyt.com/investors/)
 James Wakefield, Non-Executive Chairman                                  Via Walbrook PR

 James McCarthy, Acting Chief Executive Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                                             +44 (0)20 3470 0470
 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Deutsche Numis (Joint Broker)                                                                             +44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Michael Palser

 Allegra Finance (French Listing Sponsor)       +33 (1) 42 22 10 10

                                             r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
 Rémi Durgetto / Yannick Petit                 y.petit@allegrafinance.com

 Walbrook PR (Financial PR & IR)                                         +44 (0)20 7933 8780 or novacyt@walbrookpr.com

 Stephanie Cuthbert / Paul McManus /                                     +44 (0)7796 794 663/ +44 (0)7980 541 893

 Phillip Marriage / Alice Woodings                                        + 44 (0)7867 984 082 / +44 (0)7407 804 654

 

About Novacyt Group (www.novacyt.com (http://www.novacyt.com) )

Novacyt is an international molecular diagnostics company providing a broad
portfolio of integrated technologies and services, primarily focused on the
delivery of genomic medicine. The Company develops, manufactures, and
commercialises a range of molecular assays and instrumentation to deliver
workflows and services that enable seamless end-to-end solutions from sample
to result across multiple sectors including human health, animal health and
environmental.

 

Novacyt is headquartered in Vélizy in France with offices in the UK (in
Stokesley, Eastleigh and Manchester), Taipei (divestment pending), Singapore,
the US and Canada and has a commercial presence in over 65 countries. The
Company is listed on the London Stock Exchange's AIM market ("NCYT") and on
the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com
(http://www.novacyt.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOATLBMTMTJTBTJ